Early

Saranas Reveals Groundbreaking SAFE-MCS Study Results at CRT 2024

Retrieved on: 
Monday, March 11, 2024
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, CRT, Aortic stenosis, Physician, Risk, Early, Patient, Percutaneous coronary intervention, Henry Ford Health, MCS, PROTECT, Morristown Medical Center, Henry Ford, PCI, Bleeding, EVAR, Safety, Structural heart disease, TAVR, FDA

“This study is the first of its kind to specifically evaluate bleeding complications in patients undergoing protected PCI, with independently adjudicated results.

Key Points: 
  • “This study is the first of its kind to specifically evaluate bleeding complications in patients undergoing protected PCI, with independently adjudicated results.
  • The Saranas Early Bird Bleed Monitoring System is the first and only FDA-approved device for real-time monitoring of endovascular bleed complications.
  • “We would like to thank the excellent team of physicians and coordinators who contributed to the success of this study,” commented Mike MacKinnon, CEO and President of Saranas.
  • Saranas is dedicated to establishing a new benchmark for bleed detection during and after endovascular procedures, with the goal of improving patient outcomes and decreasing healthcare expenses overall.”

Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code

Retrieved on: 
Wednesday, February 7, 2024
CPT, Early, Arthralgia, Patient, Swelling, PLA, Risk, Pharmaceutical industry

(Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.

Key Points: 
  • (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.
  • It is estimated that up to approximately 3 million people in the US have Sjögrens Syndrome, making it one of the most prevalent autoimmune syndromes.
  • The Early Sjögrens Syndrome Test Panel is a valuable immunological tool for clinicians to both identify patients earlier, when therapeutic intervention is most effective, and to also identify patient cohorts most at risk of progression to Sjögren’s Syndrome.
  • A PLA code is a distinct, specific code assigned to a particular test and approved by the American Medical Association’s (AMA) Current Procedural Terminology (CPT) Editorial Panel.

Calysta’s FeedKind Protein Receives MARA Approval for Use in Aquaculture Feeds

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, Retail, Health, Consumer, Other Science, Environment, Sustainability, Agriculture, Natural Resources, Fitness & Nutrition, Science, Veterinary, Food, Beverage, Pets, Fermentation, Research, Early, Salmon, Weather, Protein, Methane, Aquaculture

Calysta’s FeedKind® protein has received formal approval for use in aquaculture feeds in China as the company’s joint venture with Adisseo, Calysseo, prepares to deliver first product to customers through Adisseo sales network in China.

Key Points: 
  • Calysta’s FeedKind® protein has received formal approval for use in aquaculture feeds in China as the company’s joint venture with Adisseo, Calysseo, prepares to deliver first product to customers through Adisseo sales network in China.
  • The country’s Ministry of Agriculture and Rural Affairs (MARA) has formally given Calysta’s single cell protein full approval for use in fish and shrimp feeds after an extensive evaluation process.
  • It means that protein produced by Calysseo – Calysta and Adisseo’s joint venture to produce FeedKind for the Asian aquaculture market – can now be sold and used in Chinese aquaculture feeds.
  • Calysseo’s first production plant is in Chongqing, already producing sustainable FeedKind protein for the aquaculture industry, giving producers access to an alternative to plant or animal sources for aquafeed diets.

The ABCs of Financial Crime: Consumer Education is the First Line of Defense

Retrieved on: 
Tuesday, January 30, 2024
Partnership, Nature, Coffee, Multimedia, Ageing, Crime, Research, Fear, DNA, Fraud, FINRA, Early, Silver, Retirement, Safety, Early warning, Investment, Love, Social media, FTC, Vox Media, Better Business Bureau, Education, National Council, EMV, Cryptocurrency

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Criminals have been challenging the banking and digital payments space for decades. As the financial services industry began offering safeguards like EMV chips, 3Dsecure, and biometrics, at Early Warning we've seen criminals pivot to new strategies, leveraging their technology know-how and preying on the weakest link of all -- human nature.

Key Points: 
  • Thanks to social media and many other channels, it is now easier than ever to tailor crimes to appeal to consumer emotions.
  • In 'pay yourself' scams, a criminal sends a text or call impersonating your bank or credit union.
  • Our Zelle® consumer education efforts started over five years ago with a partnership promoting financial literacy with high school students.
  • Over the years, our efforts evolved to include additional partnerships to reach broader audiences and expand resources on our website within the Financial Education Center.

Alzheon CEO Dr. Martin Tolar to Present ALZ-801/Valiltramiprosate Investigational Oral Alzheimer’s Treatment Program at Nobel Forum at Karolinska Institute in Stockholm, Sweden

Retrieved on: 
Wednesday, January 3, 2024
Science, Neurology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Karolinska Institute, Cognition, Cerebrospinal fluid, Implementation, Risk, Cerebral edema, MD, Doctor of Philosophy, Nerve, Early, Neurotoxicity, Amyloid, Patient, Safety, Therapy, Pharmaceutical industry

Alzheon Founder, President, and CEO, Martin Tolar, MD, PhD, will present an overview of investigational oral ALZ-801/valiltramiprosate anti-amyloid oligomer treatment program in the section “Optimal Treatment for Future – Combination Therapy?” moderated by Kaj Blennow, MD, PhD, on January 19 at 1:30 PM CET (7:30 AM EST).

Key Points: 
  • Alzheon Founder, President, and CEO, Martin Tolar, MD, PhD, will present an overview of investigational oral ALZ-801/valiltramiprosate anti-amyloid oligomer treatment program in the section “Optimal Treatment for Future – Combination Therapy?” moderated by Kaj Blennow, MD, PhD, on January 19 at 1:30 PM CET (7:30 AM EST).
  • “We are honored to have received an invitation to present at the prestigious Nobel Forum and discuss how ALZ-801 tablet could help shape the future therapeutic landscape for Alzheimer’s disease.
  • Alzheon's simplified approach with an oral tablet has an opportunity to transform the standard of care for millions of patients,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • “ALZ-801 efficacy data and a favorable safety profile, showing no increased risk of vasogenic edema, underscore the differentiated clinical profile of the treatment.

Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium

Retrieved on: 
Tuesday, October 31, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Amyloid, Czech Institute For International Meetings, AD, Ageing, Plaque, Organic chemistry, CSF, APOE4, MD, Symposium, Genotype, Doctor of Philosophy, Lotte New York Palace Hotel, Cerebrospinal fluid, Truist, Early, Risk, NDA, Safety, Patient, Neurotoxicity, Pharmaceutical industry, Alzheon

Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.
  • This panel will be moderated by Truist analyst, Robyn Karnauskas, PhD.
  • “Alzheon’s simple oral tablet has the potential to address a large unmet need from both an access and treatment perspective.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure neurotoxic amyloid oligomers in CSF.

BUILD-A-BEAR'S NEW HOLIDAY FILM 'GLISTEN AND THE MERRY MISSION' OPENS THIS WEEKEND IN THEATERS

Retrieved on: 
Friday, November 3, 2023
Build-A-Bear Workshop, Awe, Early, NYSE, Glistening-green tanager, Parent, Film industry, Cinemark Theatres

ST. LOUIS, Nov. 3, 2023 /PRNewswire/ -- The much anticipated, new animated holiday film by Build-A-Bear Workshop, Inc. (NYSE: BBW), is now playing at select Cinemark theaters. Build-A-Bear recently hosted a private showing of the movie in St. Louis to kick off this weekend's theatrical release, and the feedback from kids and parents alike is overwhelmingly positive and included laughing, smiles, gasping and applause. Early reviews of the movie note its charm and good cheer, as Glisten and the Merry Mission is on its way to becoming one of the season's favorite holiday movies for families.

Key Points: 
  • Viewers at Early Showing Share Smiles, Giggles and Awe for Brand's New Holiday Movie, In Theaters Now for a Limited Time
    ST. LOUIS, Nov. 3, 2023 /PRNewswire/ -- The much anticipated, new animated holiday film by Build-A-Bear Workshop, Inc. (NYSE: BBW), is now playing at select Cinemark theaters.
  • Build-A-Bear recently hosted a private showing of the movie in St. Louis to kick off this weekend's theatrical release, and the feedback from kids and parents alike is overwhelmingly positive and included laughing, smiles, gasping and applause.
  • Early reviews of the movie note its charm and good cheer, as Glisten and the Merry Mission is on its way to becoming one of the season's favorite holiday movies for families.
  • Glisten and the Merry Mission is now playing at select Cinemark theaters across the U.S. Tickets are now available for purchase by visiting Cinemark.com and on the Cinemark app.

Lung Cancer Mutation Consortium LEADER Trial Enrolls 100th Patient

Retrieved on: 
Tuesday, October 24, 2023
Patient, Early, MD, Health, LCMC, Memorial Sloan Kettering Cancer Center, Oncology, Cancer, Pharmaceutical industry

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the enrollment of one hundred patients in its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER), examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.

Key Points: 
  • NEW YORK, Oct. 24, 2023 /PRNewswire/ -- The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the enrollment of one hundred patients in its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER), examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.
  • This is the first of the LEADER trial's major milestones to be met, with many more to come.
  • Patients with early-stage lung cancers who are interested in participating in the LCMC LEADER trial should discuss the study with their oncologist to determine eligibility and the process for enrollment.
  • To learn more about LCRF and its grants program, visit www.lcrf.org
    To learn more about LCMC and the LEADER trial, visit LCRF.org/LCMC4

Supira Medical's Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference

Retrieved on: 
Friday, October 20, 2023
Exhibition, PDT, Innovation, Interventional cardiology, Use, Physician, Complex, Coronary, Cardiogenic shock, CS, Early, HCPCS Level 2, Coronary artery disease, LOS, Instituto Nacional de Medicina Genómica, Heart Institute, University of São Paulo, Cost, TCT, Paulo, Patient, Medical device, Pharmaceutical industry

LOS GATOS, Calif., Oct. 20, 2023 /PRNewswire/ -- Supira Medical, Inc., a Shifamed portfolio company, announced today that the company's percutaneous ventricular assist device (pVAD) will be showcased in multiple sessions, including a live case presentation, during the 2023 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place October 23-26 in San Francisco, CA.

Key Points: 
  • "We are extremely pleased to have the Supira System included in several outlets of the program this year," commented Dr. Nitin Salunke, President and CEO of Supira Medical.
  • "Thank you to the TCT committee for showcasing Supira in a live case presentation where we can demonstrate how our innovative technology's low profile and high continuous flow has the potential to offer significant advantages for physicians and patients requiring hemodynamic support."
  • The live case presentation from the Instituto do Coracao (InCor) in São Paulo, Brazil will take place at 11:45am PDT in the Coronary Theater, Hall F on the Exhibition Level of Moscone North.
  • Following the company's first-in-human experience, Supira Medical has expanded its clinical program, initiating a feasibility study in São Paulo, Brazil.

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer’s Disease Conference

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Cerebrospinal fluid, Doctor of Philosophy, Plasma, Amyloid, Oral, Brain, MD, Neurotoxicity, Risk, Clinical trial, Cerebral amyloid angiopathy, Safety, APOE4, Biomarker, Ageing, Cerebral edema, CSF, NDA, Organic chemistry, Genotype, Czech Institute For International Meetings, AD, Patient, Pharmaceutical industry, Medical imaging, Alzheon, Early

We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral anti-amyloid disease modifying therapy for Alzheimer’s disease,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.

Key Points: 
  • We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral anti-amyloid disease modifying therapy for Alzheimer’s disease,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • “Our efficacy data combined with a favorable safety profile with no events of vasogenic edema underscore the differentiated clinical profile of ALZ-801 tablet.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure the neurotoxic amyloid oligomers in CSF.